Ishii Koji
Department of Virology II, National Institute of Infectious Diseases.
Nihon Rinsho. 2008 Oct;66(10):1903-7.
Although vaccination has resulted in the reduction of diseases outbreaks, low levels of undesirable side effects are still a cause of concern. Traditional vaccines are made of live, attenuated, killed or fragmented pathogens, but recent progress in genetic engineering technique has enabled us to develop live attenuated mutants of several viruses and bacteria as potential vaccine vectors for antigen delivery. Such live vectors offer the advantage of delivery in a single oral, intranasal or inhalational dose, stimulating both systemic and mucosal immune responses. Here we describe the recent developments of new vaccines using recombinant viral and bacterial vectors.
尽管疫苗接种已使疾病爆发有所减少,但低水平的不良副作用仍是一个令人担忧的问题。传统疫苗由活的、减毒的、灭活的或片段化的病原体制成,但基因工程技术的最新进展使我们能够开发几种病毒和细菌的减毒活突变体作为潜在的抗原递送疫苗载体。这种活载体具有单次口服、鼻内或吸入给药的优势,可刺激全身和黏膜免疫反应。在此,我们描述了使用重组病毒和细菌载体的新型疫苗的最新进展。